Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas

Autores
Mainetti, Leandro Ernesto; Rico, Maria Jose; Fernández Zenobi, M. V.; Perroud, Herman Andrés; Roggero, Eduardo Angel; Rozados, Viviana Rosa; Scharovsky, Olga Graciela
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Metronomic chemotherapy (MCT) refers to the chronic and equally spaced administration of low doses of different chemotherapy drugs, without extended rest periods. Herein, we investigated the therapeutic efficacy of metronomic cyclophosphamide (Cy) combined with doxorubicin (Dox) in two mouse mammary adenocarcinoma models. Materials and methods: Mice were s.c. challenged with M-234p or M-406 mammary tumors, and when the tumors reached ∼150 mm3 , they were treated with: (I) no treatment (controls); (II) Cy in the drinking water (30 mg/kg body weight/day); (III) Dox (0.5 mg/kg body weight i.p. three times/week); (IV) treated as (II) + (III). Mice challenged i.v. with M-234p or M-406 tumor cells received, on day 3, the same treatments. Results: We found that MCT with Cy plus Dox inhibited tumor growth, decreased lung metastases, and increased the median survival time, while having low toxic effect. Combined MCT was more effective than each monotherapy causing decrease in VEGF serum concentration and tumor proliferation rate plus increase in tumor apoptosis. Conclusion(s): The therapeutic benefits of combined MCT with Cy and Dox on mammary adenocarcinomas together with its low toxic effect profile suggest the possibility of future translation into the clinic.
Fil: Mainetti, Leandro Ernesto. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Rico, Maria Jose. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Fernández Zenobi, M. V.. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Perroud, Herman Andrés. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Roggero, Eduardo Angel. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Scharovsky, Olga Graciela. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
Angiogenesis
Cyclophosphamide
Doxorubicin
Mammary Adenocarcinomas
Metronomic Chemotherapy
Toxic Effect
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/21683
Acceder
id CONICETDig_20c4e48ecbe92bb72bfd350d4e317a16
oai_identifier_str oai:ri.conicet.gov.ar:11336/21683
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomasMainetti, Leandro ErnestoRico, Maria JoseFernández Zenobi, M. V.Perroud, Herman AndrésRoggero, Eduardo AngelRozados, Viviana RosaScharovsky, Olga GracielaAngiogenesisCyclophosphamideDoxorubicinMammary AdenocarcinomasMetronomic ChemotherapyToxic Effecthttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Background: Metronomic chemotherapy (MCT) refers to the chronic and equally spaced administration of low doses of different chemotherapy drugs, without extended rest periods. Herein, we investigated the therapeutic efficacy of metronomic cyclophosphamide (Cy) combined with doxorubicin (Dox) in two mouse mammary adenocarcinoma models. Materials and methods: Mice were s.c. challenged with M-234p or M-406 mammary tumors, and when the tumors reached ∼150 mm3 , they were treated with: (I) no treatment (controls); (II) Cy in the drinking water (30 mg/kg body weight/day); (III) Dox (0.5 mg/kg body weight i.p. three times/week); (IV) treated as (II) + (III). Mice challenged i.v. with M-234p or M-406 tumor cells received, on day 3, the same treatments. Results: We found that MCT with Cy plus Dox inhibited tumor growth, decreased lung metastases, and increased the median survival time, while having low toxic effect. Combined MCT was more effective than each monotherapy causing decrease in VEGF serum concentration and tumor proliferation rate plus increase in tumor apoptosis. Conclusion(s): The therapeutic benefits of combined MCT with Cy and Dox on mammary adenocarcinomas together with its low toxic effect profile suggest the possibility of future translation into the clinic.Fil: Mainetti, Leandro Ernesto. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Rico, Maria Jose. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Fernández Zenobi, M. V.. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; ArgentinaFil: Perroud, Herman Andrés. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Roggero, Eduardo Angel. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; ArgentinaFil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; ArgentinaFil: Scharovsky, Olga Graciela. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaOxford University Press2013-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/21683Mainetti, Leandro Ernesto; Rico, Maria Jose; Fernández Zenobi, M. V.; Perroud, Herman Andrés; Roggero, Eduardo Angel; et al.; Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas; Oxford University Press; Annals Of Oncology; 24; 9; 5-2013; 2310-23160923-7534CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1093/annonc/mdt164info:eu-repo/semantics/altIdentifier/url/https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt164info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:07:32Zoai:ri.conicet.gov.ar:11336/21683instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:07:32.686CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas
title Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas
spellingShingle Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas
Mainetti, Leandro Ernesto
Angiogenesis
Cyclophosphamide
Doxorubicin
Mammary Adenocarcinomas
Metronomic Chemotherapy
Toxic Effect
title_short Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas
title_full Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas
title_fullStr Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas
title_full_unstemmed Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas
title_sort Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas
dc.creator.none.fl_str_mv Mainetti, Leandro Ernesto
Rico, Maria Jose
Fernández Zenobi, M. V.
Perroud, Herman Andrés
Roggero, Eduardo Angel
Rozados, Viviana Rosa
Scharovsky, Olga Graciela
author Mainetti, Leandro Ernesto
author_facet Mainetti, Leandro Ernesto
Rico, Maria Jose
Fernández Zenobi, M. V.
Perroud, Herman Andrés
Roggero, Eduardo Angel
Rozados, Viviana Rosa
Scharovsky, Olga Graciela
author_role author
author2 Rico, Maria Jose
Fernández Zenobi, M. V.
Perroud, Herman Andrés
Roggero, Eduardo Angel
Rozados, Viviana Rosa
Scharovsky, Olga Graciela
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Angiogenesis
Cyclophosphamide
Doxorubicin
Mammary Adenocarcinomas
Metronomic Chemotherapy
Toxic Effect
topic Angiogenesis
Cyclophosphamide
Doxorubicin
Mammary Adenocarcinomas
Metronomic Chemotherapy
Toxic Effect
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Metronomic chemotherapy (MCT) refers to the chronic and equally spaced administration of low doses of different chemotherapy drugs, without extended rest periods. Herein, we investigated the therapeutic efficacy of metronomic cyclophosphamide (Cy) combined with doxorubicin (Dox) in two mouse mammary adenocarcinoma models. Materials and methods: Mice were s.c. challenged with M-234p or M-406 mammary tumors, and when the tumors reached ∼150 mm3 , they were treated with: (I) no treatment (controls); (II) Cy in the drinking water (30 mg/kg body weight/day); (III) Dox (0.5 mg/kg body weight i.p. three times/week); (IV) treated as (II) + (III). Mice challenged i.v. with M-234p or M-406 tumor cells received, on day 3, the same treatments. Results: We found that MCT with Cy plus Dox inhibited tumor growth, decreased lung metastases, and increased the median survival time, while having low toxic effect. Combined MCT was more effective than each monotherapy causing decrease in VEGF serum concentration and tumor proliferation rate plus increase in tumor apoptosis. Conclusion(s): The therapeutic benefits of combined MCT with Cy and Dox on mammary adenocarcinomas together with its low toxic effect profile suggest the possibility of future translation into the clinic.
Fil: Mainetti, Leandro Ernesto. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Rico, Maria Jose. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Fernández Zenobi, M. V.. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Perroud, Herman Andrés. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Roggero, Eduardo Angel. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Scharovsky, Olga Graciela. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Background: Metronomic chemotherapy (MCT) refers to the chronic and equally spaced administration of low doses of different chemotherapy drugs, without extended rest periods. Herein, we investigated the therapeutic efficacy of metronomic cyclophosphamide (Cy) combined with doxorubicin (Dox) in two mouse mammary adenocarcinoma models. Materials and methods: Mice were s.c. challenged with M-234p or M-406 mammary tumors, and when the tumors reached ∼150 mm3 , they were treated with: (I) no treatment (controls); (II) Cy in the drinking water (30 mg/kg body weight/day); (III) Dox (0.5 mg/kg body weight i.p. three times/week); (IV) treated as (II) + (III). Mice challenged i.v. with M-234p or M-406 tumor cells received, on day 3, the same treatments. Results: We found that MCT with Cy plus Dox inhibited tumor growth, decreased lung metastases, and increased the median survival time, while having low toxic effect. Combined MCT was more effective than each monotherapy causing decrease in VEGF serum concentration and tumor proliferation rate plus increase in tumor apoptosis. Conclusion(s): The therapeutic benefits of combined MCT with Cy and Dox on mammary adenocarcinomas together with its low toxic effect profile suggest the possibility of future translation into the clinic.
publishDate 2013
dc.date.none.fl_str_mv 2013-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/21683
Mainetti, Leandro Ernesto; Rico, Maria Jose; Fernández Zenobi, M. V.; Perroud, Herman Andrés; Roggero, Eduardo Angel; et al.; Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas; Oxford University Press; Annals Of Oncology; 24; 9; 5-2013; 2310-2316
0923-7534
CONICET Digital
CONICET
url http://hdl.handle.net/11336/21683
identifier_str_mv Mainetti, Leandro Ernesto; Rico, Maria Jose; Fernández Zenobi, M. V.; Perroud, Herman Andrés; Roggero, Eduardo Angel; et al.; Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas; Oxford University Press; Annals Of Oncology; 24; 9; 5-2013; 2310-2316
0923-7534
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1093/annonc/mdt164
info:eu-repo/semantics/altIdentifier/url/https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt164
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842270006466838528
score 13.13397

Publicaciones similares